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INTRODUCTION  
Eosinophilic esophagitis (EoE) is a chronic-inflammatory disease of the esophagus, 
defined clinically by presence of symptoms of esophageal dysfunction and histologically by an 
eosinophil predominant infiltration in the esophageal mucosa.1 Due to its chronicity, EoE 
requires both short-term and long-term treatment.2 Therapeutic goals are: 1) to control 
clinical activity (resolution of symptoms); and 2) to control biological activity to avoid stricture 
formation and bolus impaction, a potentially life-threatening event. Proper diagnosis of EoE 
and successful treatment are key in EoE management.  
 
DIAGNOSIS 
A thorough medical history is the first diagnostic step (Figure 1). Typical symptoms of 
esophageal dysfunction such as solid-food dysphagia and/or recurrent bolus impactions in 
young patients with allergic comorbidities considerably increase the pre-test probability for 
EoE. To prove suspected EoE, esophagogastroduodenoscopy with biopsies taken from the 
distal and proximal esophagus is needed.3 Multiple biopsies increase diagnostic accuracy.4 At 
least 6 biopsies (3 from the proximal and 3 from the distal esophagus) should be taken. Typical 
clinical presentation together with eosophageal eosinophilia is sufficient to diagnose EoE. 
However, in case of non-typical symptoms or unusual endoscopic findings, other conditions 
leading to an eosinophilic infiltration should be considered such as reflux disease (reflux 
symptoms, signs of reflux esophagitis and/or hiatal hernia) or eosinophilic gastroenteritis 
(atypical symptoms such as dyspepsia, vomiting, diarrhea, endoscopic abnormalities in 
stomach or duodenum). 
Lately, it has become apparent that some patients can present with an EoE-like 
disease, defined as typical clinical presentation, but lack of significant eosinophilic infiltration 
in the esophagus.5 In these cases, EoE under treatment (PPI intake) and motility disorders 
have to be considered also. Review of histology slides by an expert EoE pathologist and 
immunohistochemical analyses are recommended to capture subtle histological changes such 
as basal zone hyperplasia or spongiosis and cellular infiltrates different from eosinophils 
consistent with EoE-like disease.  In unclear cases, further work-up with barium swallow and 
high-resolution manometry should be performed. 
In recent years, new diagnostic tools such as the Endoflip, esophageal string test and 
cytosponge have been studied. However, their exact role in the diagnostic algorithm have not 
been clearly defined and as of yet their routine use cannot be recommended.2 
 
TREATMENT 
Treatment of EoE consists of the 3 D’s: Drugs, Diet and Dilation.2 Dilation should be 
seen as an add-on treatment since it does not affect underlying inflammation (Figure 2). Two 
drug categories are available: Swallowed topical corticosteroids (STC) and PPI. Both should be 
used in high dose at the beginning. The most frequently applied dietary strategies are the 6-
food elimination diet (FED) with a potential step-down over time and the 2-4-6 FED step-up 
approach.6,7 In case of severe disease (frequent bolus impactions, stricturing phenotype), we 
recommend to use the most potent therapeutic agent, which are high dose STC (either 
budesonide 2x1mg or fluticasone 2x880ug or fluticasone 2x1mg if available).8 High-dose 
treatment should be continued for 6 weeks. In case of non-response or only partial response, 
expanding the induction phase to 12 weeks has been shown to be of further benefit.9 
Response to treatment should be assessed in every patient, which includes resolution 
of symptoms, endoscopic signs of inflammation and esophageal eosinophilia (= complete 
remission). In case of remission, PPI and STC doses can be lowered, although an optimal 
maintenance dose has yet to be determined. Based on recently presented data, half the 
induction dose appears to be a reasonable approach.10 If remission was achieved with empiric 
elimination diet, re-introduction of food should be initiated. Most importantly, any therapy 
should be maintained as cessation of treatment results in an EoE relapse within only few 
months.11 If histological response is not achieved, we recommend switching from PPI (“PPI 
non-response”) or elimination diet to STC. In case of less restrictive empiric elimination diets, 
a step-up approach can be taken alternatively (such as the 2-4-6 elimination diet strategy). If 
STC have failed to induce histological remission, a dietary approach or PPI high dose treatment 
might be considered. In addition, compliance and handling should be assessed as incorrect 
administration is the leading cause for refractory disease. If EoE remains active for another 8 
to 12 weeks, pseudo-refractory EoE should be ruled out (Supplementary Table 1). In case of 
true refractory disease, the monoclonal IL4-receptor antibody Dupilumab might be 
considered, although it has not been approved yet for the management of EoE.12  
If a patient shows a histological and endoscopic response, but remains symptomatic, 
we recommend endoscopic dilation. Stricturing disease can be easily missed during 
esophagogastrodudoenscopy.13 Dilation may be repeated after few weeks up to an 
esophageal diameter of 16-18mm. Dilation should always be done with caution and 




Figure 1: Algorithm for the diagnosis of eosinophilic esophagitis in adults. EGD, 
esophagogastroduodenoscopy; hpf; high-power field; peak eos count, peak eosinophil count 
in the esophageal mucosa 
Figure 2: Algorithm for the treatment of eosinophilic esophagitis in adults. PPI, proton-pump 
inhibitors; STC, swallowed topical corticosteroids 
Supplementary Table 1: Causes for pseudo-refractory EoE. 
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